Top
Main

All Outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Antiandrogens for COVID-19: real-time meta analysis of 45 studies
Covid Analysis, December 2022
https://c19early.org/aameta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani 77% 0.23 [0.08-0.66] recov. time 8 (n) 262 (n) Improvement, RR [CI] Treatment Control Cadegiani 83% 0.17 [0.06-0.51] recov. time 8 (n) 262 (n) Cadegiani 38% 0.62 [0.42-0.91] viral time 8 (n) 262 (n) McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 censored, see notes McCoy (DB RCT) 97% 0.03 [0.00-0.47] ventilation 0/134 17/134 censored, see notes McCoy (DB RCT) 91% 0.09 [0.03-0.27] hosp. 3/134 35/134 censored, see notes Cadegiani (DB RCT) 62% 0.38 [0.18-0.82] no recov. 7/44 18/43 Cadegiani (DB RCT) 44% 0.56 [0.40-0.79] recov. time 44 (n) 43 (n) Cadegiani (DB RCT) 40% 0.60 [0.44-0.81] recov. time 44 (n) 43 (n) Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] death 0/75 1/102 Cadegiani (DB RCT) 90% 0.10 [0.01-1.84] ventilation 0/75 5/102 Cadegiani (DB RCT) 86% 0.14 [0.03-0.60] hosp. 2/75 19/102 Kintor (DB RCT) 67% 0.33 [0.01-8.16] death 0/365 1/365 Kintor (DB RCT) 50% 0.50 [0.15-1.65] hosp. 4/365 8/365 Kintor (DB RCT) 67% 0.33 [0.01-8.16] death 0/360 1/361 Kintor (DB RCT) 71% 0.29 [0.06-1.37] hosp. 2/360 7/361 Kintor (DB RCT) 67% 0.33 [0.01-8.16] death 0/346 1/347 Kintor (DB RCT) 92% 0.08 [0.00-1.36] hosp. 0/346 6/347 Kintor (DB RCT) 74% 0.26 [0.13-0.51] viral+ n/a n/a Hunt 39% 0.61 [0.51-0.73] death 167/1,788 1,445/24,720 Vicenzi 93% 0.07 [0.04-0.53] death 30 (n) 39 (n) OT​1 Vicenzi 81% 0.19 [0.07-0.53] death/int. 30 (n) 39 (n) OT​1 Goren 81% 0.19 [0.03-1.28] ICU 1/12 17/36 Goren 86% 0.14 [0.02-0.94] ICU 1/12 38/65 Goren -50% 1.50 [0.15-15.1] death 1/12 2/36 Goren -35% 1.35 [0.17-11.1] death 1/12 4/65 Mareev (RCT) 11% 0.89 [0.65-1.22] no recov. 33 (n) 33 (n) CT​2 Mareev (RCT) 39% 0.61 [0.14-0.97] no disch. 14/24 20/21 CT​2 Mareev (RCT) 8% 0.92 [0.77-1.09] hosp. time 33 (n) 33 (n) CT​2 Mareev (RCT) 87% 0.13 [0.01-2.25] viral+ 0/17 3/13 CT​2 Zarehoseinz.. (RCT) 75% 0.25 [0.03-2.14] death 1/40 4/40 Zarehoseinz.. (RCT) 0% 1.00 [0.06-15.4] ICU 1/40 1/40 Ghandehari (RCT) -22% 1.22 [0.08-18.2] death 1/18 1/22 Ghandehari (RCT) 85% 0.15 [0.01-2.82] ventilation 0/18 3/22 Ghandehari (RCT) 76% 0.24 [0.03-1.91] progression 1/18 5/22 Ghandehari (RCT) 39% 0.61 [0.18-2.11] progression 3/18 6/22 Ersoy (ICU) 46% 0.54 [0.36-0.81] death 14/30 26/30 ICU patients Welén (RCT) 80% 0.20 [0.01-4.65] death 0/29 1/10 Welén (RCT) 31% 0.69 [0.07-6.81] ventilation 2/29 1/10 Welén (RCT) -133% 2.33 [1.06-5.00] no disch. 29 (n) 10 (n) Welén (RCT) -50% 1.50 [1.10-2.04] hosp. time 29 (n) 10 (n) Cadegiani (DB RCT) 78% 0.22 [0.16-0.30] death 45/423 171/355 Cadegiani (DB RCT) 79% 0.21 [0.15-0.30] death 34/423 138/355 Cadegiani (DB RCT) 45% 0.55 [0.49-0.62] no recov. 423 (n) 355 (n) Cadegiani (DB RCT) 55% 0.45 [0.39-0.52] no recov. 423 (n) 355 (n) Cadegiani (DB RCT) 33% 0.67 [0.54-0.82] hosp. time 423 (n) 355 (n) Davarpanah 78% 0.22 [0.08-0.55] hosp. 6/103 23/103 CT​2 Davarpanah 64% 0.36 [0.21-0.60] recov. time 103 (n) 103 (n) CT​2 Kotfis (RCT) 17% 0.83 [0.25-2.74] death 4/24 5/25 Kotfis (RCT) 11% 0.89 [0.35-2.28] ICU 6/24 7/25 Kotfis (RCT) 30% 0.70 [0.24-2.01] TFS 24 (n) 25 (n) Abbasi (SB RCT) 55% 0.45 [0.18-1.13] death 5/51 19/87 Abbasi (SB RCT) 34% 0.66 [0.30-1.48] ventilation 7/51 18/87 Abbasi (SB RCT) 19% 0.81 [0.42-1.59] ICU 10/51 21/87 Abbasi (SB RCT) 47% 0.53 [0.39-0.72] no recov. 51 (n) 87 (n) Gomaa (DB RCT) 91% 0.09 [0.01-1.56] death 0/25 5/25 CT​2 Gomaa (DB RCT) 91% 0.09 [0.01-1.56] ventilation 0/25 5/25 CT​2 Gomaa (DB RCT) 44% 0.56 [0.40-0.79] recov. time 25 (n) 25 (n) CT​2 Gomaa (DB RCT) 33% 0.67 [0.52-0.85] no recov. 25 (n) 25 (n) CT​2 Hsieh 88% 0.12 [0.01-2.22] death 0/117 4/143 CT​2 Hsieh 51% 0.49 [0.10-2.47] ventilation 2/117 5/143 CT​2 Hsieh 30% 0.70 [0.21-2.33] ICU 4/117 7/143 CT​2 Hsieh 88% 0.12 [0.01-2.22] no recov. 0/117 4/143 CT​2 Hsieh 36% 0.64 [0.51-0.80] viral load 117 (n) 143 (n) CT​2 Nickols (DB RCT) 18% 0.82 [0.32-1.82] death 11/62 7/34 Nickols (DB RCT) -19% 1.19 [0.50-2.84] ventilation 13/62 6/34 Nickols (DB RCT) -17% 1.17 [0.50-2.28] no recov. 15/62 7/34 Nickols (DB RCT) -20% 1.20 [0.02-92.1] hosp. time 62 (n) 34 (n) Gordon (DB RCT) 82% 0.18 [0.03-0.94] death n/a n/a Gordon (DB RCT) 76% 0.24 [0.03-1.63] ventilation time n/a n/a Gordon (DB RCT) 73% 0.27 [0.09-0.86] ICU n/a n/a Wadhwa (RCT) 72% 0.28 [0.09-0.85] progression 4/74 9/46 Wadhwa (RCT) 49% 0.51 [0.27-0.95] no disch. 13/74 16/46 Wadhwa (RCT) 18% 0.82 [0.67-1.00] recov. time 74 (n) 46 (n) Barnette (DB RCT) 55% 0.45 [0.27-0.74] death 19/94 23/51 Barnette (DB RCT) 49% 0.51 [0.33-0.76] ventilation time 98 (n) 52 (n) Barnette (DB RCT) 44% 0.56 [0.40-0.80] ICU 98 (n) 52 (n) Barnette (DB RCT) 26% 0.74 [0.57-0.97] hosp. time 98 (n) 52 (n) Montopoli 95% 0.05 [0.00-12.3] death 0/5,273 18/37,161 Montopoli 75% 0.25 [0.09-0.76] severe case 1/5,273 31/37,161 Montopoli 75% 0.25 [0.09-0.65] cases 4/5,273 114/37,161 Holt -129% 2.29 [1.59-3.32] death/ICU 16/31 148/658 Koskinen 46% 0.54 [0.06-5.16] death 1/134 3/218 Koskinen 46% 0.54 [0.06-5.16] death/ICU 1/134 3/218 Koskinen 11% 0.89 [0.34-2.34] cases 6/134 11/218 Patel 55% 0.45 [0.11-1.47] death 4/22 10/36 Patel 69% 0.31 [0.05-1.81] ventilation 22 (n) 36 (n) Patel 77% 0.23 [0.06-0.79] hosp. 22 (n) 36 (n) Bennani 95% 0.05 [0.00-2063] death 0/4 18/114 Bennani -119% 2.19 [0.37-12.9] ICU 1/4 13/114 Bennani 25% 0.75 [0.28-2.02] hosp. 2/4 76/114 Bennani 8% 0.92 [0.16-5.15] severe case 1/4 31/114 Lazzeri -23% 1.23 [0.81-1.87] death/ICU Kwon 21% 0.79 [0.10-6.40] death 1/799 7/4,412 Kwon -18% 1.18 [0.70-1.96] cases 18/799 79/4,412 Klein -124% 2.24 [0.86-5.85] death 6/304 13/1,475 Klein 7% 0.93 [0.55-1.56] cases 17/304 85/1,475 Jeon 77% 0.23 [0.08-0.64] cases case control Shaw (PSM) 6% 0.94 [0.90-0.98] cases 47 (n) 97 (n) Israel 38% 0.62 [0.41-0.91] hosp. case control Jiménez-Alcaide 33% 0.67 [0.26-1.74] death 3/11 17/50 Jiménez-Alcaide -8% 1.08 [0.54-1.83] progression 11 (n) 50 (n) Jiménez-Alcaide -68% 1.68 [0.90-3.16] cases 11/156 50/1,193 Kazan -229% 3.29 [0.61-17.7] hosp. 4/138 2/227 Kazan 29% 0.71 [0.39-1.32] cases 13/138 30/227 Schmidt (PSM) 20% 0.80 [0.46-1.34] death 25/169 44/308 Schmidt (PSM) 2% 0.98 [0.61-1.56] severe case 169 (n) 308 (n) Duarte 11% 0.89 [0.59-1.11] death 100/156 32/43 Welén 2% 0.98 [0.61-1.59] death 21/358 167/4,980 Welén 11% 0.89 [0.54-1.46] death 20/334 167/4,980 Welén -151% 2.51 [1.52-4.16] death 24/152 167/4,980 Welén -28% 1.28 [0.82-1.99] ICU 24/358 216/4,980 Welén 13% 0.87 [0.51-1.48] ICU 16/334 216/4,980 Welén 21% 0.79 [0.34-1.86] ICU 6/152 216/4,980 Welén -23% 1.23 [0.96-1.56] hosp. 126/358 1,108/4,980 Welén -24% 1.24 [0.97-1.59] hosp. 126/334 1,108/4,980 Welén -40% 1.40 [0.98-1.99] hosp. 66/152 1,108/4,980 Gedeborg -25% 1.25 [0.95-1.65] death case control Lyon 17% 0.83 [0.42-1.63] death 15/944 19/994 Lyon 7% 0.93 [0.86-1.00] cases 399/944 446/994 Lee (PSW) 21% 0.79 [0.62-0.97] severe case 76/295 727/2,427 Lee (PSW) 11% 0.89 [0.82-0.95] cases 295/3,057 2,427/36,096 MacFadden 7% 0.93 [0.88-0.98] cases n/a n/a Shah -16% 1.16 [0.68-1.98] death 148 (n) 317 (n) Shah 19% 0.81 [0.25-2.66] ventilation 148 (n) 317 (n) Shah -3% 1.03 [0.57-1.87] severe case 148 (n) 317 (n) Shah 4% 0.96 [0.52-1.77] hosp. 148 (n) 317 (n) Cousins (PSM) 69% 0.31 [0.07-1.00] ventilation 794 (n) 794 (n) Cousins (PSM) 58% 0.42 [0.22-0.78] ICU 794 (n) 794 (n) Antiandrogen COVID-19 outcomes c19early.org/aa Dec 2022 1 OT: comparison with other treatment2 CT: study uses combined treatment Favors antiandrogen Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit